ArticleSurgery2013
Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
Article in Surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Pancreastatin predicts survival in neuroendocrine tumors.Annals of surgical oncology · 2014Trial
- Article
- Short-term consumption of the modified standard American diet perturbed the metabolic balance and altered DNA damage in MMTV-PyMT transgenic mice.Breast cancer research : BCR · 2025Article
- Oxytocin/Oxytocin Receptor Signalling in the Gastrointestinal System: Mechanisms and Therapeutic Potential.International journal of molecular sciences · 2024Review
- Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment.Disease markers · 2022Article
- miRNAs in the Expression Regulation of Dopamine-Related Genes and Proteins in Endometrial Cancer.Journal of clinical medicine · 2021Article
- Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract.Frontiers in cell and developmental biology · 2021Review
- A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients.Frontiers in oncology · 2021Article
- Identification of Novel Susceptible Genes of Gastric Cancer Based on Integrated Omics Data.Frontiers in cell and developmental biology · 2021Article
- Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment.Pharmaceutics · 2020Article
- The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.Reviews in endocrine & metabolic disorders · 2020Review
- Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study.Scientific reports · 2019Article
- Oxytocin Inhibition of Metastatic Colorectal Cancer by Suppressing the Expression of Fibroblast Activation Protein-α.Frontiers in neuroscience · 2019Article
- Characterization ofScientific reports · 2018Article
- Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma.Nature genetics · 2017Article
- Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Current opinion in endocrinology, diabetes, and obesity · 2017Review
- Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.Frontiers in endocrinology · 2017Review
- Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.Clinical & experimental metastasis · 2014Article
- A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.Surgery · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLigands binding the somatostatin receptor type 2 (SSTR2) are useful for imaging and treatment of neuroendocrine tumors (NETs), but not all tumors express high levels of these receptors. The aim of this study was to evaluate gene expression of new therapeutic targets in NETs relative to SSTR2.
methodsRNA was extracted from 103 primary small bowel and pancreatic NETs, matched normal tissue, and 123 metastases. Expression of 12 candidate genes was measured by quantitative polymerase chain reaction normalized to internal controls; candidate gene expression was compared with SSTR2.
resultsRelative to normal tissue, primary NET expression of SSTR2, GPR98, BRS3, GIPR, GRM1, and OPRK1 were increased by 3, 8, 13, 13, 17, and 20-fold, respectively. Similar changes were found in metastases. Although most candidate genes showed lesser absolute expressions than SSTR2, absolute GIPR expression was closest to SSTR2 (mean dCT 3.6 vs. 2.7, P = .01). Absolute OPRK1 and OXTR expression varied greatly by primary tumor type and was close to SSTR2 in small bowel NETs but not pancreatic NETs.
conclusionCompared with the current treatment standard SSTR2, GIPR has only somewhat lesser absolute gene expression in tumor tissue but much lesser expression in normal tissue, making it a promising new target for NET imaging and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.